Recombinant pIgR Antibody Capture for dIgA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved serological protocols for monitoring infections associated with mucosal surfaces and mucosal immune responses, particularly for detecting dimeric or polymeric antibody production and purification.
Innovation Solution
The specification provides an antibody capture process involving the use of recombinant polymeric immunoglobulin receptor (pIgR) or its variants, which bind to dimeric IgA (dIgA) and form a pIgR-dIgA complex, allowing for the quantification and purification of dIgA antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibody detection methods are used, then general antibody detection is achieved, but specific detection of dimeric IgA (dIgA) is insufficient
Solution Approach 1:
The patent employs the polymeric immunoglobulin receptor (pIgR) as an intermediary molecule that specifically binds to dimeric IgA (dIgA). This intermediary enables selective capture and detection of dIgA from complex biological samples, achieving high measurement precision without requiring complex assay protocols. The pIgR acts as a bridge between the target analyte (dIgA) and the detection system.
2Reliability
If dIgA detection is improved through specific protocols, then diagnostic accuracy for mucosal infections is enhanced, but the protocol complexity increases
Solution Approach 1:
The pIgR serves as a reliable intermediary that specifically recognizes and binds dIgA, enabling accurate diagnosis of mucosal infections. This specific binding interaction ensures high diagnostic reliability by distinguishing dIgA from other antibody classes, while the standardized assay format using pIgR keeps the protocol manageable.
Solution Approach 2:
The patent utilizes the specific binding parameters of pIgR for dIgA to develop a reliable diagnostic assay. By optimizing binding conditions and detection parameters around the pIgR-dIgA interaction, the protocol achieves high diagnostic reliability without excessive complexity.
3Ease of manufacture
If dIgA purification is achieved through specific binding methods, then research and diagnostic applications are improved, but the process requires specialized reagents and procedures
Solution Approach 1:
The pIgR acts as a purification intermediary that specifically captures dIgA from complex biological samples. This specific binding enables straightforward purification protocols where dIgA is selectively bound to pIgR, washed to remove contaminants, and then eluted in purified form, simplifying the overall purification process.
Solution Approach 2:
The patent employs extraction-based purification using pIgR to selectively remove dIgA from complex biological samples. The pIgR-dIgA complex is formed, allowing dIgA to be extracted and separated from other proteins and contaminants, achieving purification through a straightforward extraction procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables efficient detection and purification of dIgA antibodies, providing a reliable method for monitoring mucosal immune responses and diagnosing infections associated with mucosal surfaces.
Implementation Method 1
contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex
Data Source
AI summary
The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM.